09:48 AM EST - Oncolytics Biotech Inc : Announces it will present new data from Cohort 1 of the GOBLET study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in ChicagoMay 30-June 3, 2025 demonstrating pelareorep's anti-tumor activity in pancreatic ductal adenocarcinoma (PDAC) - the most common form of pancreatic cancer characterized by its poor prognosis and limited treatment options. Oncolytics Biotech Inc
shares T.ONC are trading off $0.02 at $0.76.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONC%3ACC&qmodStoryID=7903566006933254
